This article is a correction to:
Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
Jianbo He1,2†
Kai Chen2†
Tiancheng Deng1Jiewei Xie1Kunjing Zhong1
Jinbo Yuan2Ziyi Wang2Zhifeng Xiao1Ronghe Gu2,3
Delong Chen4
Xiaojuan Li5*
Dingkun Lin1*
Jiake Xu2*- 1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicin, Zhuhai, China
- 2School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia
- 3Department of Orthopedics, First People’s Hospital of Nanning, Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China
- 4The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
- 5Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China
A Corrigendum on
Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity
by He J, Chen K, Deng T, Xie J, Zhong K, Yuan J, Wang Z, Xiao Z, Gu R, Chen D, Li X, Lin D and Xu J (2021). Front. Pharmacol. 12:645140. doi: 10.3389/fphar.2021.645140
In the published article, there was an error in Figure 3A about the 50 μM TRAcP picture as published. Two pictures were taken from the same cell culture well with 25 μM treatment, and partially overlapped images were obtained during photo taking, because both were from the same well. However, one image was placed as a 50 μM group, which occurred during the process of PowerPoint figure preparation due to an oversight. The corrected Figure 3 appears below.
FIGURE 3
FIGURE 3. RH attenuated osteoclast hydroxyapatite resorption and osteoclast-specific genes expression. (A) Representative images of the resorption on hydroxyapatite-coated plates and TRAcP staining after treatment of RH for 48 hr. (B) Quantification of TRAcP-positive osteoclasts numbers per well (n = 3). (C) Quantification of resorption area on hydroxyapatite surface per osteoclast (n = 3). (D–G) PCR results of osteoclast-specific genes Nfatc1, c-Fos, Ctsk, and Atp6v0d2. Gene expression levels were standardized to Hprt expression. *p < 0.05, **p < 0.01 relative to RANKL-induced control group. Scale bar = 200 μm.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: osteoclast, NFATc1, ROS, rhaponticin, bone
Citation: He J, Chen K, Deng T, Xie J, Zhong K, Yuan J, Wang Z, Xiao Z, Gu R, Chen D, Li X, Lin D and Xu J (2023) Corrigendum: Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity. Front. Pharmacol. 14:1297863. doi: 10.3389/fphar.2023.1297863
Received: 20 September 2023; Accepted: 27 November 2023;
Published: 18 December 2023.
Edited and reviewed by:
Wenzhi Yang, Tianjin University of Traditional Chinese Medicine, ChinaCopyright © 2023 He, Chen, Deng, Xie, Zhong, Yuan, Wang, Xiao, Gu, Chen, Li, Lin and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaojuan Li, lixiaojuan@jnu.edu.cn; Dingkun Lin, lindingkuntcm@126.com; Jiake Xu, jiake.xu@uwa.edu.au
†These authors have contributed equally to this work